Quanticate, the Anglo-US contract research organisation (CRO) focused mainly on data management, analysis and reporting from clinical trials, as well as post-marketing surveillance, has stepped up its presence in India by opening a new office in Bangalore.
The expansion of the CRO’s Indian facility is in “direct response to the requirements of our customers and the driving force that enabled us to significantly grow in this region”, explained Daniel Chapple, Quanticate’s executive vice president and chief commercial officer.
The higher profile means customers will benefit from “even more cost-effective offerings, particularly with the large-scale FSPs [functional service-provider contracts] that we have in place”, Chapple added.
Not just price
Price remains a “key consideration” in outsourcing of clinical trials to lower-cost locations such as India, Quanticate noted.
It is also critical, though, to ensure that the operational structure “keeps overall costs at an optimal level when taking into account oversight, communication and quality control” on both the CRO and customer side, the company stressed.
Quanticate has been “careful in its approach” to lower-cost regions, said Karen Ooms, executive vice president of operations (strategic delivery).
“The employees that are working in all our sites are not only highly experienced but also have a focus on teamwork to ensure that the high-quality deliverables and communication that Quanticate has a reputation for is not impacted,” she commented.
The CRO is expecting continued growth in all its locations on the back of a healthy pipeline of work and strong sales increases in the last two financial quarters.